#United States #New York #Securities Fraud #Pomerantz Law #Fortress Biotech

Pomerantz Law Firm's Investigation into Fortress Biotech Inc.

Pomerantz LLP, a prominent name in corporate and securities litigation, has announced that it is investigating claims on behalf of investors of Fortress Biotech Inc. (NASDAQ: FBIO). This inquiry comes after a troubling event concerning Fortress's quality control measures, which may have led to their significant drop in stock value.

Background

On October 1, 2025, Fortress Biotech revealed it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) related to the New Drug Application for its treatment CUTX-101. The CRL indicated that deficiencies in Current Good Manufacturing Practice (cGMP) had been detected at the facility responsible for producing CUTX-101. Following this news, Fortress’s stock witnessed a drastic decline, plummeting by $1.14 per share, which constituted a staggering 30.81% drop, closing at $2.56 per share.

This situation has raised alarms among investors privately and publicly regarding whether Fortress and some of its executives engaged in mismatched reporting and other potentially unlawful business practices. As a result, Pomerantz LLP has begun its investigation to determine the validity of these concerns and to protect investors' rights.

The Role of Pomerantz LLP

Founded by the late Abraham L. Pomerantz, the law firm has established a reputation over more than 85 years as a leading authority tackling securities fraud and corporate misconduct. The firm focuses on championing the rights of victims affected by breaches of fiduciary duty and involves itself vigorously in securities class action claims. Pomerantz's recognition within the legal field assures investors that their interests will be staunchly defended throughout this investigation.

The firm encourages investors who suffered losses due to Fortress's recent stock performance to contact them directly, signaling an open line of communication for those vulnerable to financial damages stemming from the company's practices. Pomerantz is well-known for securing significant recovery awards for class members in past lawsuits, reinforcing their reputation for fighting for justice and accountability.

What’s Next for Fortress Biotech Investors?

As Pomerantz LLP conducts its investigation, potential claimants are advised to join the class action process if they believe they have been adversely affected by Fortress’s recent business operations or lack of transparency concerning their manufacturing practices. Current investors should remain vigilant and seek updates from the firm regarding any developments while considering their financial strategies moving forward.

While the outcome of the investigation is uncertain, the proactive measures taken by Pomerantz affirm a commitment to corporate accountability and transparency, which have significant implications for investor confidence moving forward.

In the wake of this situation, Fortress Biotech's management faces heightened scrutiny, and the outcomes of Pomerantz's endeavors may alter the future landscape for the company significantly. As the dust settles, all eyes will be on Fortress and the impending legal actions that may unfold. Investors may find solace in knowing that a firm as reputable as Pomerantz is taking up their cause, highlighting the importance of corporate governance standards in protecting shareholder interests.

Conclusion

The investigation by Pomerantz LLP into Fortress Biotech serves as a critical reminder of the vulnerabilities that investors face. Ensuring adherence to regulations and ethical standards is paramount in maintaining investor trust and company reputation. Fortress Biotech's next steps will be crucial not only for the company itself but for all stakeholders involved in the biotechnology sector.

For further details, investors should refer to Pomerantz’s resources, where they can find additional information, or contact Danielle Peyton directly for personalized inquiries regarding their situation and options moving forward.